Maxime Dougados

1 month ago | ard.bmj.com | Josef S Smolen |Monika Schöls |Jürgen C. Braun |Maxime Dougados

The treatment target should be clinical remission/inactive disease of musculoskeletal (arthritis, dactylitis, enthesitis, axial disease) and extra-articular manifestations. This bullet point previously read: ‘A major treatment target should be clinical remission/inactive disease of musculoskeletal involvement (arthritis, dactylitis, enthesitis, axial disease), taking extra-articular manifestations into consideration’.

Apr 11, 2024 | ard.bmj.com | Anna Molto |Sofia Ramiro |Jürgen C. Braun |Maxime Dougados

Handling editor Josef S SmolenX @annamolto, @sofiaramiro82, @MProtopopov, @AlexSeprianoContributors DvdH, AM, SR and PMM drafted the manuscript. All authors reviewed and approved the manuscript before submission. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Dec 8, 2023 | ard.bmj.com | Anna Molto |Sofia Ramiro |Jürgen C. Braun |Maxime Dougados

Handling editor Josef S SmolenTwitter @annamolto, @sofiaramiro82, @MProtopopov, @AlexSeprianoContributors DvdH, AM, SR and PMM drafted the manuscript. All authors reviewed and approved the manuscript before submission. Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Jun 12, 2023 | ard.bmj.com | Anna Molto |Maxime Dougados

spondylitisankylosingpatient reported outcome measurestherapeuticsWe would like to thank Cai and Peng1 for the interest they have expressed in our recently published article ‘Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial’2 and the ARD editorial team to give us the opportunity to address their comments.